Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Turning Point Therapeutics Inc (TPTX)

Turning Point Therapeutics Inc (TPTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Turning Point Therapeutics Inc 10628 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 USA

www.tptherapeutics.com P: 858-926-5251

Description:

Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients. Their internally developed and wholly owned pipeline of next-generation tyrosine kinase inhibitors (TKIs) targets numerous genetic drivers of cancer in both TKI-na've and TKI-pretreated patients. The pervasive challenges of intrinsic and acquired treatment resistance often limit the response rate and durability of existing therapies. One of these challenges is the emergence of solvent front mutations, which are a common cause of acquired resistance to currently approved therapies for ROS1, TRK and ALK kinases. They have developed a macrocycle platform enabling us to design proprietary small, compact TKIs with rigid three-dimensional structures that potentially bind to their targets with greater precision and affinity than other kinase inhibitors.

Key Statistics

Overview:

Market Capitalization, $K 3,806,125
Enterprise Value, $K 3,378,245
Shares Outstanding, K 50,074
Annual Sales, $ 30,830 K
Annual Net Income, $ -236,550 K
Last Quarter Sales, $ 120 K
Last Quarter Net Income, $ -123,090 K
60-Month Beta -0.18
% of Insider Shareholders 8.60%
% of Institutional Shareholders 90.33%
Float, K 45,768
% Float 91.40%
Short Volume Ratio 0.32

Growth:

1-Year Return 13.89%
3-Year Return 45.64%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.48 on 08/08/22
Next Earnings Date N/A
Earnings Per Share ttm -6.90
EPS Growth vs. Prev Qtr -65.33%
EPS Growth vs. Prev Year -117.54%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

TPTX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -37.45%
Return-on-Assets % -35.61%
Profit Margin % -767.27%
Debt/Equity 0.00
Price/Sales 122.61
Price/Cash Flow N/A
Price/Book 4.76
Book Value/Share 15.97
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar